Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis

Health Policy

Volumn 82, Issue 3, 2007, Pages 330-339

  Garattini, Livio ^a   Cornago, Dante ^a   De Compadri, Paola ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Comparative analysis; Europe; In patent drugs; Pharmaceutical policy

Indexed keywords

ANTIMIGRAINE AGENT; ORAL CONTRACEPTIVE AGENT; SPASMOLYTIC AGENT;

ARTICLE; BELGIUM; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG LEGISLATION; DRUG RESEARCH; EUROPE; FRANCE; GERMANY; ITALY; MEDICAL EXPERT; MEDICAL LITERATURE; NETHERLANDS; PATENT; PATHOLOGY; PHARMACOECONOMICS; REIMBURSEMENT; SPAIN; UNITED KINGDOM;

COMMERCE; DRUG THERAPY; EUROPE; GOVERNMENT REGULATION; HUMANS; INPATIENTS; INTERVIEWS; LEGISLATION, DRUG; REIMBURSEMENT MECHANISMS;

EID: 34250736162     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.11.004     Document Type: Article

References (32)

1. Mossialos E., and Oliver . An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. International Journal of Health Planning and Management 20 (2005) 291-306
2. Barton J.H., and Emanuel E.J. The patent based pharmaceutical development process: rationale, problems, and potential reforms. The Journal of the American Medical Association 294 16 (2005) 2075-2082
3. Joppi R., Bertelè V., and Garattini S. Disappointing biotech. British Medical Journal 331 (2005) 895-897
4. Apolone G., Joppi R., Bertelè V., and Garattini S. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. British Journal of Cancer 93 (2005) 504-509
5. Vernon J.A. Examining the link between price regulation and pharmaceutical R&D investment. Health Economics 14 (2005) 1-16
6. Danzon P.M., Wang Y.R., and Wang L. The impact of price regulation on the launch delay of new drugs-evidence from 25 major markets in the 1990s. Health Economics 14 3 (2005) 269-292
7. Taylor R.S., Drummond M.F., Salkeld G., and Sullivan S.D. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. British Medical Journal 329 7472 (2004) 972-975
8. Drummond M.F., O'Brien B., Stoddart G.L., and Torrance G.W. Methods for the economic evaluation of health care programmes (1997), Oxford Medical Publications, Oxford
9. Trueman P., Drummond M., and Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 19 6 (2001) 609-621
10. Schokkaert E., and Van de Voorde C. Health care reform in Belgium. Health Economics 14 (2005) S25-S39
11. BESPE. A proposal for methodological guidelines for economic evaluation of pharmaceuticals. Brussels: BESPE; 1995.
12. De Pouvourville G. The influence of economic evaluation studies on decision-making in France. In: Eberhardt S., Stoklossa C., and von der Schulenburg J.M.G. (Eds). EUROMET 2004: the influence studies on health care decision-making (2005), IOS Press, Amsterdam
13. Giuliani G., Selke G., and Garattini G. The German experience in reference pricing. Health Policy 44 (1998) 73-85
14. Puig-Junoy J. What is required to evaluate the impact of pharmaceutical reference pricing?. Applied Health Economics and Health Policy 4 2 (2005) 87-98
15. Stargardt T., Schreyogg J., and Busse R. Pharmaceutical reference pricing in Germany: definition of therapeutic groups price setting through regression procedure and savings. Gesundheitswesen 67 (2005) 469-478
16. Krankenkassen claim reference price savings. SCRIP; February 23, 2006 [on line publication].
17. Anonymous. Five firms take German Krankenkassen to court over reference pricing. SCRIP 2004;3045:3.
18. Anonymous. German health ministry on controversial reference price move. SCRIP 2004;3010:4.
19. §35 Festbeträge für Arznie und Verbandmittel. Neugefasst durch G vom 21.12.1992 (BGBI S 2266).
20. Eberhardt S., and von der Schulenburg J.M. The influence of economic evaluation studies on decision-making in Germany. In: Eberhardt S., Stoklossa C., and von der Schulenburg J.M.G. (Eds). EUROMET 2004: the influence studies on health care decision-making (2005), IOS Press, Amsterdam
21. Ghislandi S., Krulichova I., and Garattini L. Pharmaceutical policy in Italy: towards a structural change?. Health Policy 72 (2005) 53-63
22. Giovanni F., and Jommi C. The new pharmaceutical policy in Italy. Health Policy 46 1 (1998) 21-41
23. Garattini L., De Compadri P., Clemente R., and Cornago D. Economic evaluations in Italy: a review of the literature. International Journal of Technology Assessment 19 4 (2003) 685-697
24. De Compadri P., Cornago D., and Garattini L. The influence of economic evaluation studies on decision-making in Italy. In: Eberhardt S., Stoklossa C., and von der Schulenburg J.M.G. (Eds). EUROMET 2004: the influence studies on health care decision-making (2005), IOS Press, Amsterdam
25. CVZ, College Voor Zorgverzekeringen. Dutch guidelines for pharmacoeconomic research (Report). Amstelveen; 1999.
26. Koopmanschap M.A., and Rutten F.F.H. The influence of economic evaluation studies on decision-making in the Netherlands. In: Eberhardt S., Stoklossa C., and von der Schulenburg J.M.G. (Eds). EUROMET 2004: the influence studies on health care decision-making (2005), IOS Press, Amsterdam
27. Rovira J., and Darbà J. Pharmaceutical pricing and reimbursement in Spain. The European Journal of Health Economics 2 1 (2001) 39-43
28. Puig Junoy J. Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 67 (2004) 149-165
29. Antonanzas F. The influence of economic evaluation studies on decision-making in Spain. In: Eberhardt S., Stoklossa C., and von der Schulenburg J.M.G. (Eds). EUROMET 2004: the influence studies on health care decision-making (2005), IOS Press, Amsterdam
30. Drummond M., Nixon J., and Wilson P. The influence of economic evaluation studies on decision-making in the United Kingdom. In: Eberhardt S., Stoklossa C., and von der Schulenburg J.M.G. (Eds). EUROMET 2004: the influence studies on health care decision-making (2005), IOS Press, Amsterdam
31. Lundkvist J., Jonsson B., and Rehnberg C. The costs and benefits of regulations for reimbursement of new drugs. Health Policy 79 2-3 (2006) 337-344
32. Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 81 (2007) 17-28